Abbvie Inc (ABBV)

$257.12 +2.12 (0.83%)
Market Cap 450.53B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.08
Forward PE 17.85
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 4,308,800
Avg Vol 5,209,052
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 59%
Beta 0.29
Analysts Strong Sell
Price Target $277.87

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Scanlz
Scanlz Sep. 12 at 5:04 PM
$ABBV People will always get sick and the need for medicine will never stop.
0 · Reply
JCJustCharting
JCJustCharting Sep. 12 at 4:10 PM
$ABBV anyone wanting another read of this stock, check me out https://x.com/jc_justcharts/status/2098801213592445066?s=46
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 4:04 AM
$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 3:50 AM
$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:51 PM
$SLS $ABBV We Know from the IDMC Unblinded ACTUAL Phase 3 MOS and Median Follow up Data from the Interim Analysis: • Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:45 PM
$SLS $ABBV For the Inch Thick Mile Wide Short Lowlife -- only. Can you explain the implications of the VIALE-M and VIALE-T Phase 3 Trial FAILURES? VIALE-M Phase 3 Combining Oral Az+VEN FAILED for AML FIRST REMISSION MAINTENANCE - BAT for the SLS P3 Control ARM Patients in Second Remission FAILED a Phase 3 For First Remission Maintenance -- Explain....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:17 PM
$SLS $MRNA $ABBV BAT for the SLS P3 Control ARM/ Onureg +VEN Failed in First Remission (CR1) VIALE-M FAILED. Onureg - as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. We Know from the IDMC Unblinded P3 MOS and Median Follow up data ... Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. it is not complicated
0 · Reply
parcha
parcha Sep. 11 at 10:01 PM
$ABBV Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:07 PM
$SLS $MRNA $ABBV BAT / Onureg +VEN Failed in First Remission (CR1) Onureg as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:02 PM
$SLS $ABBV Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival
0 · Reply
Latest News on ABBV
Ipsen considers building production site in U.S., WSJ says

2026-09-11T10:15:37.000Z - 1 day ago

Ipsen considers building production site in U.S., WSJ says

AbbVie Declares Quarterly Dividend

Sep 10, 2026, 2:17 PM EDT - 2 days ago

AbbVie Declares Quarterly Dividend

AbbVie's migraine treatment meets late-stage study goal

Sep 10, 2026, 9:04 AM EDT - 2 days ago

AbbVie's migraine treatment meets late-stage study goal

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

2026-09-10T13:00:14.000Z - 2 days ago

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

Sep 10, 2026, 8:55 AM EDT - 2 days ago

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

AbbVie price target raised to $315 from $300 at HSBC

2026-09-10T10:26:53.000Z - 2 days ago

AbbVie price target raised to $315 from $300 at HSBC

AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 9, 2026, 10:15 AM EDT - 3 days ago

AbbVie Transcript: Wells Fargo 21st Annual Healthcare Conference

AbbVie price target raised to $282 from $276 at BofA

2026-09-08T12:10:17.000Z - 4 days ago

AbbVie price target raised to $282 from $276 at BofA

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

Sep 5, 2026, 8:30 AM EDT - 7 days ago

Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.

AIRS LLY NVO

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

2026-09-03T13:25:47.000Z - 9 days ago

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

AbbVie's blood cancer drug meets late-stage trial goals

Sep 3, 2026, 9:22 AM EDT - 9 days ago

AbbVie's blood cancer drug meets late-stage trial goals

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Sep 3, 2026, 9:15 AM EDT - 9 days ago

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

AbbVie completes acquisition of Apogee for $135.11 per share in cash

2026-09-03T12:41:00.000Z - 9 days ago

AbbVie completes acquisition of Apogee for $135.11 per share in cash

APGE

AbbVie Completes Acquisition of Apogee Therapeutics

Sep 3, 2026, 8:34 AM EDT - 9 days ago

AbbVie Completes Acquisition of Apogee Therapeutics

APGE

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 3, 2026, 8:05 AM EDT - 9 days ago

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

2026-09-01T12:15:42.000Z - 11 days ago

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Sep 1, 2026, 8:05 AM EDT - 11 days ago

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Aug 31, 2026, 8:00 AM EDT - 12 days ago

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 16 days ago

AbbVie submits Skyrizi application to the EMA

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Aug 27, 2026, 2:00 AM EDT - 16 days ago

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Emily Field: Large pharma companies are going to continue looking at biotech

Aug 24, 2026, 10:45 AM EDT - 19 days ago

Emily Field: Large pharma companies are going to continue looking at biotech

IBB MRK MRNA XLV

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Aug 21, 2026, 7:45 AM EDT - 22 days ago

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie price target raised to $303 from $298 at Piper Sandler

2026-08-20T10:55:24.000Z - 23 days ago

AbbVie price target raised to $303 from $298 at Piper Sandler

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Aug 18, 2026, 8:00 AM EDT - 25 days ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 26 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-17T08:29:38.000Z - 26 days ago

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 4 weeks ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 4 weeks ago

AbbVie price target raised to $260 from $246 at Evercore ISI

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 5 weeks ago

AbbVie upgraded to Buy from Hold at Erste Group

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T13:35:25.000Z - 5 weeks ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

2026-08-04T12:10:59.000Z - 5 weeks ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Earnings release: Q2 2026

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 6 weeks ago

AbbVie Quarterly report: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 6 weeks ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 6 weeks ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 6 weeks ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 6 weeks ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 6 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 7 weeks ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 1 month ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 2 months ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 2 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 2 months ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 2 months ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 2 months ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 2 months ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Scanlz
Scanlz Sep. 12 at 5:04 PM
$ABBV People will always get sick and the need for medicine will never stop.
0 · Reply
JCJustCharting
JCJustCharting Sep. 12 at 4:10 PM
$ABBV anyone wanting another read of this stock, check me out https://x.com/jc_justcharts/status/2098801213592445066?s=46
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 4:04 AM
$SLS $MRNA $ABBV TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 12 at 3:50 AM
$SLS $ABBV 19 Month MOS for CR1 First Remission on BAT - is actually just 17.3 months when equalized for the time in treatment vs from Enrollment in REGAL. Any way you look at it 19 or 17 months In CR1 translates to 8 or 9 months MOS in Second Remission CR2 - just like all the doctors treating Regal patients are saying and the same as the Avalon 8.8 month MOS. https://haematologica.org/article/view/14308
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:51 PM
$SLS $ABBV We Know from the IDMC Unblinded ACTUAL Phase 3 MOS and Median Follow up Data from the Interim Analysis: • Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:45 PM
$SLS $ABBV For the Inch Thick Mile Wide Short Lowlife -- only. Can you explain the implications of the VIALE-M and VIALE-T Phase 3 Trial FAILURES? VIALE-M Phase 3 Combining Oral Az+VEN FAILED for AML FIRST REMISSION MAINTENANCE - BAT for the SLS P3 Control ARM Patients in Second Remission FAILED a Phase 3 For First Remission Maintenance -- Explain....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 11:17 PM
$SLS $MRNA $ABBV BAT for the SLS P3 Control ARM/ Onureg +VEN Failed in First Remission (CR1) VIALE-M FAILED. Onureg - as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. We Know from the IDMC Unblinded P3 MOS and Median Follow up data ... Gps P3 MOS for CR2 will come in > 34 Months - Longer than SOC for CR1. it is not complicated
0 · Reply
parcha
parcha Sep. 11 at 10:01 PM
$ABBV Investment bank Wells Fargo set a 12-month price target for pharmaceutical company AbbVie of $300 on Thursday, giving the Chicago-based company an overweight rating, which is equivalent to a buy. Analyst Mohit Bansal said the AbbVie has solid patent protection for its core business units and that he is expecting updates on the firm’s work in oncology and neuroscience. “We rate ABBV Overweight, as we think that the stock is reasonably priced for strong growth into the next decade, coupled with long-term patent protection for key businesses. We expect mid-stage pipeline to come to limelight in next 12 months, which should help with multiple expansion,” https://www.cnbc.com/2026/09/10/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:07 PM
$SLS $MRNA $ABBV BAT / Onureg +VEN Failed in First Remission (CR1) Onureg as a single Agent MOS for First Remission (CR1) was 24.7 Months. GPs Phase 2 MOS in the same First Remission (CR1) setting was > 67.6 months. it is not complicated
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 8:02 PM
$SLS $ABBV Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:39 PM
$SLS $MRNA $ABBV added Venetoclax to Onureg for First Remission Patients in the VIALE-M Trial. Onureg / Oral Aza MOS is 24.7 months ADDING VEN did not increase Survival Gps Phase 3 MOS - in the ONGOING P3 will come in 34/36 Months ... Gps Phase 3 CR2 MOS - in the ONGOING P3 will come in 34/36 Months ... Longer MOS in CR2 than SOC in CR1... GPs Phase 2 MOS in CR1 was 67.6 Months GPS Phase 2 MOS in CR2 was 21 months - an older, Less Healthy all MRD+ setting, with less Gps Dosing.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:33 PM
$SLS $MRNA $ABBV DOES EVERYONE KNOW -- BAT for the SLS P3 CONTROL ARM - FAILED 3 Large Phase 3 Trials ????? FULL TITLE: Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) FAILED ... FAILED the Control ARM Second Remission Patients in the SLS REGAL Phase 3 Trial Too....
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:19 PM
$SLS $MRNA $ABBV ABBVIE INVESTIGATIONAL PRODUCT: Venetoclax (ABT-199) EU CT: FULL TITLE: Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) FAILED ... FAILED the Control ARM in the SLS REGAL Phase 3 Trial Too....
0 · Reply
quezoitm
quezoitm Sep. 11 at 7:18 PM
$ABBV $MRNA $SLS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 7:17 PM
$SLS $MRNA $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 6:29 PM
$SLS With all the FUD... Yes Best Available Treatment BAT for Control Patients - Aza+VEN - FAILED 3 Large Phase 3 Trials conducted by $ABBV VIALE-T FAILED for Post Transplant Maintenance VIALE-M Failed for AML FIRST REMISSION Maintenance Aza+VEN is Failing for AML SECOND Remission Maintenance too. its even more toxic and ineffective in the Later Stage. They TRIED 8 Different Oral/IV/subq dosing regimes... all failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 11 at 5:43 PM
$SLS $MRNA Onureg / Oral Az / Aza is the Standard of Care for AML First Remission Patients (CR1) - Median Overall Survival 24.7 Months. Gps Phase 2 MOS for the same exact First Remission (CR1) setting was not reached and GREATER Than > 67.6 months. Onureg / SOC 24.7 Gps > 67.6 Onureg was combined with Venetoclax in the VIALE-M Phase 3 trial conducted by $ABBV for AML First Remission (CR1) Patients - the MOS is unkwown because the TRIAL FAILED. VIALE-T Phase 3 for AML Post Transplant Maintenance also - FAILED.
0 · Reply
StochAlpha
StochAlpha Sep. 11 at 11:16 AM
Top 5 Buys · Sep 11, 2026 $FROG and $ROKU both showing RS and institutional scores in the 85-90 range. $ABBV quietly sitting at institutional accumulation of 89 — institutions have been loading this one for some time now. Diverse group today. The scan follows the setup, not the sector.
0 · Reply
Mantraset3
Mantraset3 Sep. 11 at 5:10 AM
$ABBV Botox makes everything better 💰
0 · Reply
Gebinator
Gebinator Sep. 10 at 9:13 PM
$SLS $JNJ $MRK there we have it -- $ABBV wins the potential 'spoiler' award according to 39% of 104 poll respondents --thanks! Whether some transaction for SLS009 to pair with Venclexta or the whole enchilada with GPS, it appears $ABBV is still a contender to take some or all 🏆 Pfizer not too far behind at 31% and Lilly keeping its 'dark horse' status with about a quarter of the vote (24%). Meanwhile, AstraZeneca far behind (6%). Are there more 'dark horses' still in the running? ...
0 · Reply